COVID-19 therapy: What weapons do we bring into battle?

被引:17
|
作者
Vitalino de Almeida, Sinara Monica [1 ,2 ,3 ]
Santos Soares, Jose Cleberson [2 ]
dos Santos, Keriolaine Lima [2 ]
Ferreira Alves, Josival Emanuel [3 ]
Ribeiro, Amelia Galdino [2 ]
Tenorio Jacob, Iris Trindade [2 ]
da Silva Ferreira, Cindy Juliane [1 ]
dos Santos, Jessica Celerino [1 ]
de Oliveira, Jamerson Ferreira [2 ]
de Carvalho Junior, Luiz Bezerra [3 ]
Alves de Lima, Maria do Carmo [2 ]
机构
[1] Univ Pernambuco, Lab Biol Mol, Garanhuns, PE, Brazil
[2] Univ Fed Pernambuco, Lab Quim & Inovacao Terapeut LQIT, Dept Antibiot, Recife, PE, Brazil
[3] Univ Fed Pernambuco, Lab Imunopatol Keizo Asami LIKA, Recife, PE, Brazil
关键词
Coronavirus; SARS-CoV-2; COVID-19; Antiviral; Repurposed drugs; RESPIRATORY SYNDROME CORONAVIRUS; CYCLOSPORINE-A; SPIKE PROTEIN; EBOLA-VIRUS; BIOLOGICAL EVALUATION; CONVALESCENT PLASMA; SARS CORONAVIRUS; NUCLEOSIDE ANALOGS; ANTIVIRAL ACTIVITY; POTENT INHIBITOR;
D O I
10.1016/j.bmc.2020.115757
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Urgent treatments, in any modality, to fight SARS-CoV-2 infections are desired by society in general, by health professionals, by Estate-leaders and, mainly, by the scientific community, because one thing is certain amidst the numerous uncertainties regarding COVID-19: knowledge is the means to discover or to produce an effective treatment against this global disease. Scientists from several areas in the world are still committed to this mission, as shown by the accelerated scientific production in the first half of 2020 with over 25,000 published articles related to the new coronavirus. Three great lines of publications related to COVID-19 were identified for building this article: The first refers to knowledge production concerning the virus and pathophysiology of COVID-19; the second regards efforts to produce vaccines against SARS-CoV-2 at a speed without precedent in the history of science; the third comprehends the attempts to find a marketed drug that can be used to treat COVID-19 by drug repurposing. In this review, the drugs that have been repurposed so far are grouped according to their chemical class. Their structures will be presented to provide better understanding of their structural similarities and possible correlations with mechanisms of actions. This can help identifying anti-SARS-CoV-2 promising therapeutic agents.
引用
收藏
页数:26
相关论文
共 50 条
  • [1] COVID-19: What do we know?
    Marshall, Steve
    Duryea, Michael
    Huang, Greg
    Kadioglu, Onur
    Mah, James
    Palomo, Juan Martin
    Rossouw, Emile
    Stappert, Dina
    Stewart, Kelton
    Tufekci, Eser
    [J]. AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS, 2020, 158 (05) : E53 - E62
  • [2] Pandemic preparedness beyond COVID-19: what we know, what we do, and what we do not
    Pericas, Juan M.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2024, 30 (05) : 574 - 575
  • [3] COVID-19 vaccine: what are we doing and what should we do?
    Candelli, Marcello
    [J]. LANCET INFECTIOUS DISEASES, 2022, 22 (05): : 569 - 570
  • [4] Asthma and COVID-19: What do we know?
    Sarioglu, Nurhan
    [J]. TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2020, 68 (02): : 141 - 147
  • [5] Ivermectin in COVID-19: What do we know?
    Pandey, Sanjay
    Pathak, Subodh Kumar
    Pandey, Apurva
    Salunke, Abhijeet Ashok
    Chawla, Jasneet
    Sharma, Aryan
    Sharma, Sarthak
    Thivari, Praveen
    Ratna, Harish V. K.
    [J]. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2020, 14 (06) : 1921 - 1922
  • [6] COVID-19 and animals: What do we know?
    Gonultas, Serkan
    Karabagli, Murat
    Bastug, Yavuz
    Cilesiz, Nusret Can
    Kadioglu, Ates
    [J]. TURKISH JOURNAL OF UROLOGY, 2020, 46 (04): : 249 - 252
  • [7] Resuscitation in COVID-19 patients: What do we know and what should we do?
    Yilmaz, Ezgi
    Arsava, Ethem Murat
    Topcuoglu, Mehmet Akif
    [J]. CARDIOLOGY JOURNAL, 2020, 27 (05) : 656 - 657
  • [8] The Battle Against COVID-19: Where Do We Stand Now?
    Negahdaripour, Manica
    [J]. IRANIAN JOURNAL OF MEDICAL SCIENCES, 2020, 45 (02) : 81 - 82
  • [9] Patient Nutrition and Probiotic Therapy in COVID-19: What Do We Know in 2021?
    Hawrylkowicz, Viktoria
    Lietz-Kijak, Danuta
    Kazmierczak-Siedlecka, Karolina
    Solek-Pastuszka, Joanna
    Stachowska, Laura
    Folwarski, Marcin
    Parczewski, Milosz
    Stachowska, Ewa
    [J]. NUTRIENTS, 2021, 13 (10)
  • [10] Covid-19: What do we know about "long covid"?
    Mahase, Elisabeth
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 370